Tempo reale stimato
Altri mercati azionari
|
Variaz. 5gg | Var. 1 gen. | ||
1,775 USD | +1,43% | -0,28% | -24,47% |
28/03 | XERIS BIOPHARMA HOLDINGS, INC. : via al Buy per Oppenheimer | ZM |
06/03 | Transcript : Xeris Biopharma Holdings, Inc., Q4 2023 Earnings Call, Mar 06, 2024 |
Attività
Numero di dipendenti: 377
Vendite per attività
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Gvoke, Keveyis and Recorlev
93,6
%
| 109 | 99,1 % | 153 | 93,6 % | +40,36% |
Royalty, Contract and Other
6,4
%
| 1 | 0,9 % | 11 | 6,4 % | +971,07% |
Vendite per regione
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 110 | 100,0 % | 164 | 100,0 % | +48,68% |
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
Founder | 60 | 01/01/05 | |
Paul Edick
CEO | Chief Executive Officer | 67 | 05/10/21 |
Steven Pieper
DFI | Director of Finance/CFO | 47 | 01/01/21 |
John Shannon
PSD | President | 62 | 05/10/21 |
Ken Johnson
CTO | Chief Tech/Sci/R&D Officer | 61 | 01/10/21 |
Allison Wey
IRC | Investor Relations Contact | - | - |
Kevin McCulloch
PRN | Corporate Officer/Principal | - | 01/10/18 |
Beth Hecht
LAW | General Counsel | 60 | 01/10/21 |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
John Johnson
BRD | Director/Board Member | 66 | 05/10/21 |
Jeffrey Sherman
BRD | Director/Board Member | 69 | 05/10/21 |
Marla Persky
BRD | Director/Board Member | 68 | 05/10/21 |
Paul Edick
CEO | Chief Executive Officer | 67 | 05/10/21 |
Garheng Kong
BRD | Director/Board Member | 49 | 01/10/21 |
John Schmid
BRD | Director/Board Member | 60 | 05/10/21 |
Director/Board Member | 65 | 05/10/21 | |
Dawn Halkuff
BRD | Director/Board Member | 53 | 05/10/21 |
Ricki Fairley
BRD | Director/Board Member | 67 | 27/03/23 |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 1 | 148 253 615 | 142 712 322 ( 96,26 %) | 0 | 96,26 % |
Coordinate società
Xeris Biopharma Holdings, Inc.
1375 West Fulton Street Suite 1300
60607, Chicago
+
http://www.xerispharma.comSettore
Vendite per attività
Revisioni EPS
Variaz. 1 gen. | Capi. | |
---|---|---|
-24,47% | 259 Mln | |
+33,79% | 664 Mrd | |
+29,61% | 567 Mrd | |
-6,86% | 354 Mrd | |
+19,72% | 330 Mrd | |
+4,38% | 286 Mrd | |
+13,60% | 234 Mrd | |
+5,41% | 199 Mrd | |
-9,94% | 196 Mrd | |
-4,49% | 148 Mrd |
- Borsa valori
- Azioni
- Azione XERS
- Società Xeris Biopharma Holdings, Inc.